RxDoctor Payments Data

Hung Dang, MD

Internal Medicine · Houston, TXNPI 1568403889

Payments from drug & device makers

$2,588in general payments, 2019–2025

Across 156 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$837
  • AstraZeneca$375
  • Bayer$344
  • Amgen$286
  • GSK$144
  • Boehringer Ingelheim$133
  • plus $468 from 12 others

What the payments were for

  • Food & beverage$2,57499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,588 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$52,438
Medicare patients
95
Services billed
783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin254$425,241
GlyxambiEmpagliflozin/Linagliptin173$267,910
FarxigaDapagliflozin Propanediol186$261,979
RybelsusSemaglutide57$150,910
ProliaDenosumab80$139,113
VascepaIcosapent Ethyl207$132,509
EliquisApixaban50$82,678
KerendiaFinerenone43$48,668
InvokanaCanagliflozin27$45,104
XareltoRivaroxaban22$31,159
TradjentaLinagliptin18$23,904
Omega-3 Acid Ethyl Esters256$14,924
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,891
Rosuvastatin Calcium1,398$10,461
Lantus SolostarInsulin Glargine,hum.Rec.Anlog76$10,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$133$717,055445 claims
AstraZenecaFarxiga, Breztri Aerosphere$375$272,870197 claims
Novo NordiskRybelsus$837$150,91057 claims
AmgenProlia$286$139,11380 claims
PfizerEliquis$54$82,67850 claims
BayerKerendia$344$48,66843 claims
GSKBreo Ellipta, Arexvy, Shingrix$144$14,32843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →